Assessing lumps and bumps in dogs is one of the most frequent, and most consequential, tasks in small animal practice. A canine mass cannot be called benign or malignant by sight or by feel. Two masses that look identical on the exam table can be a harmless lipoma and a mast cell tumor. This guide sets out a clear diagnostic workflow for dermal and subcutaneous masses: how to triage what you find, when to aspirate versus monitor, how to tell the common masses apart, and where non-invasive screening now fits as a first step.
Why 'wait and see' is the expensive option
Palpation feels informative, but it is a poor test. Firmness, mobility, and size overlap heavily across benign and malignant masses. A soft, mobile, slow growing mass is often a benign mass, such as a lipoma, yet soft tissue sarcomas and some mast cell tumors can present exactly the same way. That overlap is why visual and manual assessment alone misses cancers that were treatable at the time of the visit.
The scale of the gap is real. Many canine dermal and subcutaneous masses never reach a definitive diagnosis, often because the workup stalls at monitor and recheck. Every recheck cycle that passes on an untested malignancy is a cycle in which margins get wider, options get narrower, and the owner conversation gets harder.
The diagnostic workflow, step by step
A repeatable sequence keeps decisions consistent across the whole clinical team and gives the owner a clear rationale at each stage.
- History and physical exam. Record onset, growth rate, and any change in a mass the owner has noticed. Measure and map every mass with calipers, and log location, depth (dermal or subcutaneous), consistency, and fixation. Photograph where possible so change is objective, not remembered.
- Risk stratification. Flag higher risk features: rapid growth, ulceration, fixation to underlying tissue, a hard immovable lump, inflammation, pain, or any mass in a high consequence site. Signalment matters too, since some breeds and older dogs carry higher tumor risk.
- Non-invasive screening as a first step. A non-invasive scan can triage which masses need immediate cytology and which are very unlikely to be malignant, before a needle is placed. This is where VISTA iQ sits, and it is covered in detail below.
- Fine needle aspiration and cytology. For any mass flagged as moderate or higher risk (I.e above the 10% cancer risk threshold), or any mass an owner wants resolved, aspirate and examine cytology. Cytology is fast and low cost and will identify many tumor types, such as mast cell tumors, lipomas, and inflammatory lesions.
- Histopathology to confirm and assess grade and margins. When cytology is inconclusive, or when a malignancy is identified and grading and margins will guide surgery, biopsy for histopathology is the reference standard. Grade and margins drive the treatment plan.
Signalment: which dogs deserve extra suspicion
Signalment does not diagnose a mass, but it should shift your index of suspicion and your recheck intervals. Age is the strongest factor: tumor incidence climbs steadily in dogs over seven, and a new mass in a senior dog earns a faster workup than the same mass in a two year old. Breed matters for specific tumor types. Boxers, Boston Terriers, Bulldogs, Pugs, and Retrievers are over-represented for mast cell tumors. Large breeds carry more soft tissue sarcomas. Overweight, middle aged dogs accumulate lipomas, which cuts both ways: they have more truly benign masses, and more places for a malignancy to hide among them.
The practical rule: in a high risk signalment, lower your threshold for sampling and shorten your recheck interval. In a young dog with a fast growing dome shaped lesion, a histiocytoma is likely, but likely is a probability statement, not a diagnosis, and cytology is cheap confirmation.
Documenting masses so change is objective
Most monitoring failures are documentation failures. A mass that was never measured cannot be shown to have grown, and ‘about the size of a pea’ in the previous note is useless six months later. A workable documentation protocol takes under two minutes per mass:
- Map it. Record the anatomic location precisely (left dorsal thorax, 4 cm caudal to the scapula), or mark it on a body map diagram in the record. Dogs with multiple masses need a numbered map, or masses get confused between visits.
- Measure it. Calipers, two dimensions, in millimeters. Estimations drift; calipers do not.
- Characterize it. Depth (dermal or subcutaneous), consistency, mobility, fixation, overlying skin changes.
- Photograph it. With a scale reference in frame. A photo settles the did-it-change question instantly.
- Log the decision. Screened, sampled, or monitored, and the recheck date. The plan is part of the record, not a verbal agreement.
Telling the common lumps and bumps apart
| Mass type | Typical presentation | Malignant potential |
| Lipoma | Soft, mobile, subcutaneous, slow growing, often multiple in older dogs | Benign, but can mimic (and mask) liposarcoma and other masses |
| Mast cell tumor | Highly variable: can look like a wart, a lipoma, or an inflamed lump; may wax and wane | Malignant. The great imitator, which is why it is the key rule out |
| Soft tissue sarcoma | Firm, deep, can feel deceptively slow and soft early on | Malignant, locally invasive, wide margins needed |
| Histiocytoma | Fast growing, dome shaped, often in young dogs, frequently self resolves | Benign, but growth rate alarms owners and mimics malignancy |
| Sebaceous cyst | Discrete, dermal, may discharge, slow | Benign, but confirmation still warranted if changing |
| Cutaneous papilloma (wart) | Cauliflower texture, often viral in young dogs | Benign, usually self limiting |
| The one you cannot afford to miss Mast cell tumors are the classic imitator. They can present as a soft movable lump indistinguishable from a lipoma. Any assumption of just a fatty lump without sampling or screening is the single most common way a mast cell tumor is sent home. When in doubt, treat a fatty feeling mass as unproven, not benign. | ||
When to aspirate versus when to monitor
The safest default is that a new or changing mass is sampled or screened, not simply watched. Monitoring without any test is reserved for masses that have been previously confirmed benign and are stable. Use the framework below.
Sample or screen now
- Any new mass in a dog, especially if the owner cannot date its onset.
- A mass that is growing, changing shape or color, ulcerated, or newly painful.
- A hard, fixed, or deep mass, or any mass over a surgically difficult site.
- Any fatty feeling mass that has not been confirmed by cytology, because mast cell tumors imitate lipomas.
Reasonable to monitor
- A mass already confirmed benign on prior cytology or histopathology that remains stable in size and character.
- With a documented recheck interval and clear owner instructions to return sooner if anything changes.
Where non-invasive screening fits: VISTA iQ
VISTA iQ is a non-invasive screening tool that acts as the new first step in the workflow above, before the needle. It uses Heat Diffusion Imaging (HDI) technology: benign and malignant tissue diffuse heat differently, and the device’s AI system returns a cancer risk result (low, moderate, or high) rather than raw thermal data the clinician has to interpret. The scan takes about 40 seconds and the risk result is available in under two minutes.
Used at triage, VISTA iQ helps answer the question that starts every workup: does this mass need cytology now. Of masses the system reports as low risk, it is designed to rule out cancer in the scanned mass with a 98% negative predictive value, which gives clinical confidence when reassuring an owner about a low risk mass. In select cases it flags specific tumor types such as mast cell tumors with 90% specificity. It is decision support for when to aspirate versus monitor, and it does not replace cytology or histopathology where those are indicated.
The owner conversation: getting to yes on the workup
The clinical workflow only runs if the owner agrees to it, and most refusals are really misunderstandings. Three conversation habits raise diagnostic compliance without pressure. First, name the uncertainty honestly: ‘I cannot tell you what this is by feeling it, and neither can anyone else. Some cancers feel exactly like harmless fatty lumps.’ Owners decline tests they think are optional confirmations of what the vet already knows; they rarely decline tests framed as the only way to know. Second, present the ladder, not the summit: a screening scan or an aspirate today, not a conversation about surgery and oncology referrals. Owners commit to small next steps. Third, put the recheck on the calendar before they leave. ‘Watch it and call me if it changes’ converts poorly; a booked recheck with a documented baseline converts well.
When an owner still declines, document the recommendation and the decline, hand them a measuring reference, and set a reminder. A declined aspirate in March can become an accepted one in May if the mass has measurably grown and the record proves it.
Common pitfalls that let malignancies slip through
- The single mass exam. The owner points at one lump; the dog has four. Every mass gets found and mapped at every visit, because the one the owner did not notice is the one that matters statistically.
- The fatty aspirate full stop. Fat on the slide is reassuring, not final. A needle can pass through subcutaneous fat and miss the lesion beside it. Any later change reopens the question.
- Monitoring without a baseline. A watch and wait plan without measurements is a plan to argue about memory at the next visit.
- Anchoring on the last diagnosis. A dog with three confirmed lipomas can still grow a mast cell tumor as the fourth mass. Each new mass is a new question.
- Letting cost end the conversation. When an owner cannot fund cytology today, a non-invasive screen or a documented two week recheck is a better outcome than nothing. Offer the ladder.
Making it work in a busy clinic
The workflow only helps if it survives a full waiting room. Two practical points make it stick. First, screening is nurse and technician led, so a scan can be added to the intake without pulling a veterinarian off another case. Second, a documented result at the point of care changes the owner conversation from a vague recommendation to a clear next step, which improves both compliance and the odds that a real malignancy is worked up while it is still small.
A decision framework you can use tomorrow
- Find and map every mass at every visit, not only the one the owner mentioned.
- Assume nothing from palpation. A soft mass is not a confirmed benign mass.
- Screen at triage to decide, fast, which masses need cytology now.
- Aspirate at risk and unresolved masses, and confirm malignancies on histopathology before definitive surgery.
- Document the decision and the recheck plan so change is measured, not recalled.
Frequently Asked Questions
How can you tell if a dog’s lump is cancerous?
You cannot tell from appearance or palpation alone. Firmness, size, and mobility overlap between benign and malignant masses. A reliable answer needs a test: non-invasive screening to triage risk, fine needle aspiration with cytology, and histopathology to confirm and grade when a malignancy is found.
Should every lump on a dog be aspirated?
As a default, every new or changing mass should be screened or sampled rather than simply watched. Monitoring without a test should be reserved for masses already confirmed benign that remain stable. Non-invasive screening can help decide which masses need cytology immediately.
What is the most commonly missed cancerous lump in dogs?
The mast cell tumor is the classic missed cancer, because it can present as a soft, movable lump that feels like a lipoma. That is why any fatty feeling mass should be treated as unproven until cytology or screening confirms it.
How fast do cancerous lumps grow in dogs?
Growth rate varies widely. Some malignancies grow quickly and some are deceptively slow, while some benign masses such as histiocytomas grow fast and then resolve. Because growth rate alone is unreliable, any change in a mass is a reason to test rather than to wait.
